ReviewJournal of medical microbiology2025
The Ebola virus - going beyond the bleeding edge.
Review in Journal of medical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Five Hot Topics in Tropical Medicine: 2025.Infectious disease reports · 2026Review
- Tropical infectious diseases and skin manifestations: a diagnostic framework.Current opinion in infectious diseases · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ebola virus (EBV) genus is responsible for severe viral haemorrhagic illness caused by a group of viruses belonging to the Filoviridae family. Five species have been identified as causative agents for Ebola virus disease (EVD). The EBV (Zaire) strain is the most predominant organism involved in recorded EVD outbreaks and has been reported as the most virulent. EVD was first identified in the Democratic Republic of Congo in 1976 and has occurred in sporadic outbreaks over the last few decades with the most recent episode in Uganda over the period September 2022-January 2023. EVD is zoonotic in nature with bats as reservoir host and humans become infected via a spillover event from contact with infected animals. EVD is transmitted through contact with infected bodily fluids. It is considered fatal with a high mortality and high infectivity rate. Treatment is generally supportive with the availability of intravenous fluids and medicines. Research into vaccine development is ongoing. EVD is a particular public health concern given the potential for global spread during an outbreak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.